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ABSTRACT 
Background: Despite an abundance of soy interventions, the effect of soy isoflavones 
prior to curative treatment for localized prostate cancer on biochemical recurrence has not 
been evaluated.   
Objective: To determine if short-term supplementation with soy isoflavones prior to 
curative treatment delays or prevents biochemical recurrence in men with localized 
prostate cancer. 
Design: Electronic medical record reviews were conducted in February 2013 to gather 
follow-up data on men (n = 86) previously enrolled in the Role of Isoflavones in Prostate 
Cancer study. Data collected included demographics, treatment modalities and 
complications, clinical and pathological staging, Gleason score, body mass index (BMI), 
comorbidities, prostate-specific antigen (PSA), PSA recurrence, time to recurrence, and 
death status. Fisher Exact test was used to compare rates of biochemical recurrence. 
Mann-Whitney U test was used to compare time to recurrence. Time to event analyses 
were performed using Kaplan-Meier plots with Log-rank test applied to assess statistical 
significance. Logistic regression analysis using PSA recurrence (yes/no) as a response 
was used adjusting for age and race. 
Results: Sixty-six men were included in the final analysis. p < 0.05 was considered 
statistically significant. Overall rate of recurrence was 9%, with a rate of 9.3% in the soy 
group and 8.8% in the placebo group (p = 0.63). Mean time to recurrence overall was 33 
± 22 months, with 27 ± 26 months in the soy group and 40 ± 20 months in the placebo 
group (p = 0.53). There was no difference in survival times to biochemical recurrence or 
death between groups.  
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Conclusion: Short-term supplementation with soy isoflavones prior to curative treatment 
for localized prostate cancer was not found to significantly affect biochemical recurrence 
in this study. 
 
  
	   v	  
TABLE OF CONTENTS 
CHAPTER I: INTRODUCTION .................................................................................... 1 
Statement of Purpose ................................................................................................... 2  
CHAPTER II: REVIEW OF LITERATURE ................................................................ 3 
Introduction ................................................................................................................. 3 
Background ................................................................................................................. 3 
 PSA in diagnosis and monitoring .......................................................................... 3 
 Curative treatment options .................................................................................... 4 
 Biochemical recurrence of prostate cancer ............................................................ 5 
 Soy and soy isoflavones ........................................................................................ 7 
 Soy isoflavones and prostate cancer ...................................................................... 8 
Limitations ................................................................................................................. 12 
CHAPTER III: MATERIALS AND METHODS ........................................................ 13 
Study overview .......................................................................................................... 13 
Data collection ........................................................................................................... 13 
Statistical analysis ..................................................................................................... 15 
CHAPTER IV: RESULTS ............................................................................................. 17 
Rate of recurrence ...................................................................................................... 17 
Time to recurrence ..................................................................................................... 17 
CHAPTER V: DISCUSSION ........................................................................................ 19 
Implications ............................................................................................................... 19 
Limitations ................................................................................................................. 20 
Future Research ......................................................................................................... 20 
Conclusion ................................................................................................................. 21 
CHAPTER VI: REFERENCES ...................................................................................  22 
APPENDICES  ................................................................................................................ 31 
 
	   1	  
CHAPTER I: INTRODUCTION 
Geographic variations in prostate cancer incidence suggest an environmental 
influence on development of the disease. Epidemiological studies show a lower incidence 
of prostate cancer in Asian populations compared to Western populations, though 
prostate cancer incidence and mortality is increasing in Asian countries as diet becomes 
Westernized (1,2). Likewise, studies show a rising incidence of prostate cancer among 
Japanese and Chinese men who migrate to the U.S. (2,3), suggesting some nutritional 
component is responsible for the environmental influence on prostate cancer.  
Soy and soy isoflavones are nutritional components that may explain geographic 
variations in prostate cancer rates. Case-control studies in Japan find soy isoflavone 
consumption to be associated with a decreased risk of prostate cancer, possibly due to 
initiation of cancer cell apoptosis and tumor growth inhibition via effects on the cell cycle 
(4). Soy isoflavone consumption in Asian countries typically ranges from 25-50 mg/day 
versus a typical intake of 2-3 mg/day in the U.S. (5). Isoflavones may offer benefits for 
prostate health beyond cancer prevention to include cancer recurrence following treatment. 
Supplementing men with soy isoflavones concurrently with radiation therapy has led to a 
decrease in urinary, sexual, and intestinal side effects and may even enhance the effect of 
radiation therapy, but the long-term effects on biochemical recurrence have not been evaluated 
(6). 
Biochemical recurrence is determined through serial measurements of prostate-
specific antigen (PSA) and is managed with androgen deprivation therapy, radical 
prostatectomy, and/or radiation therapy. Side effects of androgen deprivation therapy include 
increased fat deposition, osteoporosis, and sexual dysfunction; side effects of prostatectomy 
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and radiation therapy include incontinence, bowel dysfunction, and erectile dysfunction. 
Identifying a method to prevent or delay biochemical recurrence after curative treatment can 
help circumvent the negative side effects of current treatment options and reduce prostate-
specific mortality. 
Statement of purpose 
 The question addressed by this research study was as follows: does soy isoflavone 
supplementation prior to curative treatment for localized prostate cancer delay 
biochemical recurrence? To address this question, the study focused on the following 
aims:  
1. To compare the rate of biochemical recurrence (defined as prostate-specific 
antigen [PSA] ≥0.2 ng/mL for radical prostatectomy; PSA nadir + 2 ng/mL for 
radiation therapy) and the length of time to recurrence in the treatment versus 
placebo group. I hypothesize that the rate of biochemical recurrence in the 
treatment group will be lower than that of the placebo group and that the length of 
time to recurrence will be greater in the treatment group than in the placebo 
group. 
2. To compare rate and time to biochemical recurrence after stratification by 
treatment type (radical prostatectomy versus radiation therapy) in the treatment 
and placebo groups. I hypothesize that men supplemented with soy isoflavones 
who underwent prostatectomy will have lower rates and longer time to recurrence 
than men in the placebo group and men supplemented with isoflavones who were 
treated with radiation therapy. 
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CHAPTER II: REVIEW OF LITERATURE 
INTRODUCTION 
 Prostate cancer is projected to affect 238,590 U.S. men and lead to cancer-specific 
mortality in approximately 12% of these men in 2013 (7). In a Swedish cohort study of 
6,849 men, 80-90% of prostate cancer diagnoses were identified as localized cases (8), 
and more than 75% of men with localized disease will undergo radical prostatectomy or 
radiation therapy (9,10). Data show approximately 30% of men managed with a curative 
intent will experience prostate cancer recurrence (11–13), ranging from 20-40% (14). 
This review examines the effect of soy and soy isoflavone interventions on 
prostate cancer biomarkers with an emphasis on biochemical recurrence.  
BACKGROUND 
PSA in diagnosis and monitoring 
PSA is a serine protease (15) that increases in instances of benign prostatic 
hyperplasia, inflammation, infection, and prostate cancer (16,17). The advent of PSA as a 
tool for screening after 1988 (18) led to an increase in prostate cancer diagnoses, 90% of 
which are localized or regionalized cases that would not have been detected previously 
(19,20). Though PSA is generally recognized as a poor marker for prostate cancer due to 
its lack of specificity and false positive and negative results, it is still widely used for 
screening and detection (21). PSA velocity and PSA doubling time (PSADT) are types of 
PSA kinetics used for monitoring PSA over time. PSADT in particular may be useful for 
stratifying the risk of cancer progression in men who have undergone radical 
prostatectomy (22), while preoperative PSA concentrations may predict biochemical 
progression and metastases post-prostatectomy (11,17).   
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Curative treatment options 
 Treatment options for localized prostate cancer consist of radical approaches, 
primarily radical prostatectomy and/or radiation therapy (11), conservative approaches 
such as watchful waiting (WW) or active surveillance (AS), and neoadjuvant or adjuvant 
hormonal therapy (23). Radical prostatectomy and radiation therapy are administered 
with a curative intent and will be emphasized in this review. 
Radical Prostatectomy 
 Radical prostatectomy consists of complete removal of the prostate and seminal 
vesicles using either a retropubic, laparoscopic, or robotic approach and is typically 
performed on men who have a life expectancy >10 years (23,24). Radical prostatectomy 
is the gold standard for intermediate- to high-risk prostate cancer due to lower rates of 
metastases, prostate cancer-specific mortality, and overall death compared to watchful 
waiting (23,25), but the procedure carries significant risk. Adverse effects of the 
procedure may include major bleeding, incontinence, bowel dysfunction, and impotence 
(24), though symptoms may improve gradually throughout the first year post-operation 
(26). A recent review of evidenced found that robotic-assisted radical prostatectomy led 
to improved outcomes, faster physical recovery, and improved, though not significantly, 
biochemical recurrence-free survival (27). 
Radiation Therapy 
Radiation therapy includes external beam radiation and brachytherapy. External 
beam radiation is administered directly to the entire prostate (24). Treatment lasts 
approximately 6-7 weeks, during which the patient may receive neoadjuvant hormonal 
therapy to shrink the prostate through androgen deprivation (23,24). Radiation therapy is 
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most often used in men >65 years who have a greater risk of metastases (23). Side effects 
of external beam radiation include cystitis, hematuria, incontinence, erectile dysfunction, 
and secondary malignancies (24). 
Brachytherapy involves the placement of radioactive seeds directly in the prostate 
(23,24). The seeds contain iodine or cesium and are placed permanently, typically in 
amounts of 80-100 seeds (23). Risks of brachytherapy are often less significant than those 
of radical prostatectomy or external beam radiation, but patients may still experience 
aggravated urinary tract symptoms, urinary retention, hematuria, erectile dysfunction, and 
rectal inflammation (24). Brachytherapy is better suited for less aggressive cancers and 
men whose prostate volume is <50 cm3 (23,24).  
Biochemical recurrence of prostate cancer 
Definition and criteria 
 Following curative treatment, PSA is measured every 3 months to monitor for 
biochemical recurrence and observe trends in PSA over time (11). Definitions of 
biochemical recurrence differ by treatment. Due to the removal of all prostatic tissue in 
radical prostatectomy, recurrence is defined as a single post-operation PSA ≥0.2 ng/mL 
(22). Since the prostate remains intact following radiation therapy, PSA will still be 
present at low concentrations. As a result, biochemical recurrence is defined as PSA nadir 
+ 2 ng/mL (28).  
Biochemical recurrence is estimated to occur in approximately one third of men 
(11–14,29). One study of 5,277 men from the CaPSURE database found greater 
incidence of recurrence in radiation therapy patients versus radical prostatectomy patients 
(63% vs. 23%, respectively) (29), which is consistent with previous reports of 15%-33% 
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for radical prostatectomy (30,31), but slightly higher than data for radiation therapy 
(37%-48%) (32,33). Higher rates of biochemical recurrence after radiation therapy 
suggest an incomplete elimination of malignant cells compared to prostatectomy. 
Natural history of biochemical recurrence 
 Time to biochemical recurrence varies by treatment. One study reported mean 
times of 34 months in prostatectomy patients and 38 months in radiation therapy patients 
(29). Additional studies reported median time to recurrence of 19-40 months after 
prostatectomy (13,14,22,34) and 34-41 months after radiation therapy, though some 
patients also received androgen deprivation therapy after primary treatment (34). A 
retrospective study focusing on obese men (BMI ≥30 kg/m2) found a median time to 
recurrence after radical prostatectomy of only 10 months and a significantly higher PSA 
nadir, leading to the conclusion that men with a BMI ≥30 kg/m2 have a greater risk of 
biochemical recurrence post-prostatectomy (35). These results are supported by previous 
studies that also find higher rates of recurrence in U.S. men with a BMI ≥30 kg/m2 (36), 
though obesity does not appear to predict recurrence in Asian men (37,38). Finally, a 
review of sixteen studies of men who completed primary treatment found a 21% increase 
in the risk of biochemical recurrence for each 5 kg/m2 increase in BMI (39). 
Salvage treatment 
Patients with biochemical recurrence have several treatment options, consisting of 
adjuvant androgen deprivation therapy administered immediately or delayed until 
metastases (14), or salvage therapy, which includes prostatectomy, radiation therapy, or 
cryotherapy (11). Due to the androgen dependence of most prostate tumors, the 
diminishing of androgens in the body leads to tumor shrinkage and subsequent 
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improvement of symptoms (24). In cases of failed androgen deprivation therapy, the 
cancer is referred to as castration-resistant (24). Side effects of androgen deprivation 
therapy include hot flashes, osteoporosis, increased fat storage, sexual dysfunction, loss 
of libido, and increased cardiovascular morbidity (11). Androgen deprivation therapy is 
the most common treatment for biochemical recurrence (11), with one study reporting 
60% and 94% of men receiving treatment after prostatectomy and radiation therapy, 
respectively (29). A recent study of U.S. veterans found 3%, 11%, and 21% mortality 
rates from prostate cancer recurrence at 5, 10, and 15 years (40). Since the majority of 
men will die of causes unrelated to their prostate cancer, it is important that the benefits 
of salvage treatment outweigh the risks (11). Even better, however, would be the 
identification of a safe, non-toxic approach to help prevent or delay biochemical 
recurrence. 
Soy and soy isoflavones 
One novel approach to delaying or preventing biochemical recurrence is the use 
of soy and soy isoflavones. Soy foods contain a class of phytochemicals known as 
phytoestrogens, which exert both estrogenic and anti-estrogenic effects on the body 
(41,42). Major classes of phytoestrogens include isoflavones, flavones, coumestans, 
lignans, and silbenes (41), but the primary phytoestrogens of interest to prostate cancer 
are isoflavones (43). There are multiple pathways by which soy isoflavones are thought 
to affect prostate tumors in addition to their hormonal effects, mainly through induction 
of apoptosis and cell differentiation, inhibition of cell proliferation and angiogenesis, and 
exertion of antioxidant properties (44–46). The interest in soy and prostate cancer started 
with epidemiological studies that found lower incidence of prostate cancer in Asian men, 
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who are known to consume more soy than men in the U.S. (2) and have plasma and 
serum phytoestrogen concentrations 10 times greater than amounts found in the Western 
populace (47–49). Furthermore, rates of biochemical recurrence may be lower in Asian 
countries than in Western countries, with one study reporting 23.6% of men in Japan 
experiencing recurrence after external beam radiation (50), which is slightly lower than 
the 33% seen in the U.S. for all treatments.  
Soy isoflavones exist in a combination of two forms: the unconjugated aglycone 
form, consisting of genistein, daidzein, and glycitein, or the sugar-conjugated glucosidic 
form, which includes genistin, daidzin, and glycitin (42,49). Glucoside conjugates are not 
bioavailable until the glucoside is digested, thereby releasing the aglycone form for 
absorption (51). Isoflavone content of soybeans varies depending on the growing 
environment, but each soybean contains approximately 1.2-3.3 mg isoflavones per gram 
of dry weight (49). In individuals with a daidzein-metabolizing phenotype, gut bacteria 
further metabolize daidzein to equol, a compound that is suspected to be partially 
responsible for the health benefits of soy (52). Studies show 30%-50% of Western 
populations produce equol (53,54), compared to up to 80% in Japan, China, and Korea 
(55). 
SOY ISOFLAVONES AND PROSTATE CANCER 
Isoflavones in prevention and progression 
Isoflavones are commonly studied in relation to prostate cancer prevention and 
progression, but previous interventions in cancer patients have not evaluated long-term 
follow-up or recurrence rates. The majority of studies found no significant decreases in 
PSA (56–59), though one study found a significant decrease in biopsy-detected cancer 
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(59). When compared to men following their usual diets, a significant decrease in PSA 
was seen in men who underwent comprehensive lifestyle changes consisting of a low-fat 
vegan diet with soy (1 serving/day of tofu plus 58 g/day of soy protein powder beverage), 
vitamin E, selenium, fish oil, and vitamin C supplementation accompanied by stress 
reduction, exercise, and weekly support groups (60), though the effects cannot be 
attributed to soy alone. Finally, in a study of men awaiting prostatectomy, subjects 
consuming soy grits (117 mg mixed isoflavones/day) had a significant percent change in 
total PSA compared to a control group and had a significant change in androgen index 
compared to men consuming soy grits plus linseed (61). These data do not strongly 
support the use of soy or soy isoflavones alone in prostate cancer prevention.  
Isoflavones in biochemical recurrence 
 The few treatment options for men with rising PSA following curative treatment 
come with negative side effects that decrease quality of life, thus highlighting the need to 
find alternative ways of delaying or preventing biochemical recurrence. Previous studies 
have not explored the effect of isoflavone supplementation before curative treatment on 
rate of recurrence after treatment. Studies have used soymilk (62,63), soy beverage or soy 
protein isolate (64–67), or capsules/tablets in order to isolate the effects of soy 
isoflavones (68–70). Isoflavone content ranges from 65-900 mg/day, though amounts are 
omitted from two studies (63,69). Durations of interventions range from 4 weeks (66) to 
12 months (62), and primary endpoints include a variety of PSA analyses, including 
absolute, rise, slope, percent or absolute change, PSADT, and velocity, as well as 
hormonal markers and overall response to soy. 
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Isoflavone capsules 
Early studies used isoflavone capsules providing 200-900 mg/day of isoflavones 
for approximately 6 months. Studies reported PSA stabilization in both prostatectomy 
and hormone therapy patients with rising PSA (64,68), as well as a significant decrease in 
the rate of PSA rise in the hormone therapy patients (68). However, 35 of 52 men (67%) 
with rising PSA continued to biochemical progression following the 900 mg/day 
intervention (64). These studies suggest the ability of isoflavones to stabilize PSA and 
reduce rate of rise (68), but not to prevent or delay recurrence (64). Comparing these 
results also suggests that a higher dose does not necessarily confer greater treatment 
effects. Finally, both studies waited until PSA was already rising post-treatment to 
provide isoflavones, rather than supplementing prior to treatment as proposed here.   
Soy combined with other bioactives 
Several studies used supplements combined with multiple bioactives. One study 
used a supplement containing green tea, 100 mg isoflavones, 100 mg other 
phytoestrogens, and carotenoids, as well as margarine fortified with vitamin E, 
phytosterols, and selenium. Results showed a nonsignificant increase in PSADT after 
treatment, but significant decreases in free PSA, testosterone, dihydrotestosterone, and 
free androgen index (65). Other studies combined soy and lycopene with hopes of 
enhancing the effects of both. Ten weeks of supplementation with capsules containing 
soy isoflavones, lycopene, silymarin, and antioxidants resulted in a significant decrease in 
PSA slope and 2log PSA slope (69). Another study found a significant reduction in rate of 
PSA rise in hormone-refractory and hormone-sensitive patients after 6 months of 
lycopene or lycopene + isoflavone supplements; however, hormone-refractory patients in 
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the lycopene-only group had a significantly greater decrease in rate of PSA rise, 
suggesting a benefit from lycopene rather than soy (70). A similar crossover study using 
either lycopene or soy protein isolate with 80 mg/day of isoflavones observed PSA 
reduction in 34% of men at the end of 8 weeks (66). Results from these studies are 
confounded by the use of multiple bioactives, though a synergistic effect is probable. As 
in studies using isoflavone capsules, these studies waited to supplement men until PSA 
was already rising after treatment. 
Soy foods  
The most recent studies used soy beverages or commercially available soy 
products to provide isoflavones. Soymilk or soy beverages providing 65-141 mg/day of 
isoflavones (62,67) in men with biochemical recurrence have led to reductions in PSA 
and significant decreases in PSA slope in up to 30% of subjects. Investigators also 
observed a significantly lower yearly PSA increase of 20% compared to the expected 
value of 56% (62). In one study, men had a median PSADT that was 32% longer post-
intervention, though 17% of patients had a >50% decrease in PSADT (67). Overall in this 
study, a decline in PSA or increase in PSADT was seen in 41% of patients. A 
retrospective study of 10 men consuming commercially available soy foods who had 
androgen deprivation-naïve or castration-resistant prostate cancer reported 50% of 
patients with progression, 40% of men with PSA reductions and negative PSA kinetics or 
PSA stabilization, and 10% with a decrease in PSA velocity and PSADT (63). The 
median response lasted 24 months before one subject experienced progression, which 
suggests response to soy can be lost. Based on these results, providing isoflavones in soy 
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foods does not offer any obvious benefit over capsules. Again, these studies did not 
supplement men before treatment.  
Limitations 
 None of the currently published studies evaluate the effect of soy consumption 
before treatment on biochemical recurrence. The wide variation in supplements used in 
intervention studies creates a challenge when comparing results. Routes of isoflavone 
delivery include soymilk, soy beverages, soy protein powder, capsules/tablets, and whole 
foods. Supplements also vary in isoflavone content, composition, and structure, with 
differing percentages of genistein, daidzein, and glycitein, as well as differences in 
predominant isoflavone structure (aglycone versus glucoside). Finally, several studies 
analyze supplements containing several bioactives, making it difficult to determine which 
component is responsible for treatment effects. 
 Nearly one third of men will experience biochemical recurrence after curative 
treatment for prostate cancer. Due to the high probability of developing negative side 
effects from salvage therapies, it is prudent to find safe, non-toxic methods of preventing 
or treating biochemical recurrence. Previous soy isoflavone interventions show both 
neutral and beneficial effects, though results are limited by small sample sizes and the use 
of multiple bioactives, and comparison of results is complicated by methodological 
differences between studies. Furthermore, previous studies have only implemented soy 
after biochemical recurrence has occurred, rather than prior to curative treatment.  
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CHAPTER III: MATERIALS AND METHODS 
Study overview 
Data were extended from the Role of Isoflavones in Prostate Cancer study (71) a 
four-week, double-blind, randomized, placebo-controlled trial conducted using 86 men 
with histologically confirmed prostate cancer scheduled to undergo prostatectomy. Men 
in the parent study were randomized to receive commercially available soy isoflavone 
capsules (51 mg/d aglycone units) or identical placebo capsules for up to one month prior 
to curative treatment.  
The present study built upon this clinical trial by gathering follow-up data to 
compare the natural history of prostate cancer in the soy isoflavone group to the placebo 
group. Data were abstracted from electronic medical records (EMR) and stored using a 
secure online database management program. The primary aim was to compare rate and 
time to biochemical recurrence between soy and placebo arms, defined as PSA ≥0.2 
ng/mL for radical prostatectomy and PSA nadir + 2 ng/mL for radiation therapy. A 
secondary aim compared rate and time to biochemical recurrence in subjects who 
underwent prostatectomy (n = 46) versus radiation therapy (including interstitial 
brachytherapy and external beam radiation) (n = 20) in the treatment and placebo groups.  
Data collection 
 Study participants were men with localized prostate cancer (n = 86) recruited from 
the University of Kansas Hospital (KUH) Urology Clinic and the Kansas City Veterans 
Affairs Medical Center (VAMC) as part of the Role of Isoflavones in Prostate Cancer study 
(71). Men were included if they had histologically confirmed prostate cancer, were willing to 
avoid soy for 90 days before the study and were willing to avoid soy and other dietary or 
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herbal supplements during the study. Participants were excluded from analysis if they were 
lost to follow-up, defined as having no PSA value documented after curative treatment, if they 
did not receive curative treatment, or if PSA value failed to reach zero after radical 
prostatectomy. Participants provided informed consent for future research as part of IRB-
approved protocols from each institution. Patients were excluded from the parent study if they 
met any of the following criteria: 1) were receiving concurrent chemotherapy, radiation, or 
neoadjuvant hormone therapy, 2) consumed soy foods within 90 days of enrollment, or 3) had 
a known history of soy allergy or intolerance. Soy intake was assessed at baseline using a 
validated soy foods questionnaire (72). Urine was collected at 2 weeks for analysis of 
isoflavones and their metabolites (O-desmethylangolensin [ODMA], daidzein, 
dyhydrodaidzein [DHD], genistein, glycitein, and equol) and creatinine. Compliance was 
based on creatinine-adjusted urinary daidzein concentration due to daidzein being the 
primary isoflavone in the supplements. Participants in the placebo group were considered 
noncompliant if creatinine-adjusted daidzein was ≥ 10 nM/mL, indicating the participant 
was consuming soy.  
Data were abstracted from EMR on the VAMC and KUMC campuses following 
Protocol Review and Monitoring Committee (PRMC) and Human Subjects Committee 
(HSC) approval. Information abstracted from the EMR was recorded and stored on 
KUMC’s HIPAA-certified servers using Research Electronic Data Capture (REDCap), an 
online tool for secure database management (73). Access to the EMR was granted only to 
individuals directly involved with the study following the completion of KUMC and 
VAMC human subjects training and HIPAA certification.  
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Data were abstracted and verified by two researchers over a 3-week period in 
February 2013. Data obtained from EMR included demographic information, treatment 
modalities and complications, clinical and pathological staging, Gleason score, body 
mass index (BMI), comorbidities, PSA, PSA recurrence, time to recurrence, and death 
status (Appendix A). Age was calculated by taking the difference between date of birth 
and date of curative treatment. Time to recurrence was calculated using date of curative 
treatment and date of documented biochemical recurrence.  
Statistical analysis 
The data were summarized with descriptive statistics on the baseline 
characteristics of the subjects on study and presented as mean ± standard deviation 
(Table 1). The data were then examined for normality using histograms and box plots 
(Appendix B). Due to the small proportion of recurrence and lack of normality, non-
parametric methods were used to study the association between the biochemical 
recurrences with the soy intake status. Fisher Exact test was used to compare the rate of 
biochemical recurrences in the soy versus placebo groups and prostatectomy versus 
radiation therapy groups. Fisher Exact test is appropriate when the sample size is low, 
which calculates the exact probabilities of the occurrences of the observed frequencies, 
given the assumptions of independence and the size of the marginal frequencies (row and 
column totals of 2×2 contingency table). Mann-Whitney U test was used to compare the 
time to recurrence in the soy versus placebo group and also prostatectomy versus 
radiation therapy groups. Time to recurrence of prostate cancer was analyzed using 
Kaplan-Meier analysis method. The survival curves over time for the two groups were 
plotted and log-rank tests were used to assess the significance. Similarly, survival times 
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in the two groups were analyzed using Kaplan-Meier plots followed by log-rank test. 
Finally, logistic regression analysis using PSA recurrences (yes/no) as response was 
carried out adjusting for possible confounding variables age and race. SPSS® for 
Macintosh, Version 20, (SPSS Inc. Chicago) was used for all statistical analyses (74).                
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CHAPTER IV: RESULTS 
Eight patients were lost to follow-up, 3 patients remained under active surveillance or 
watchful waiting, 8 patients had a post-prostatectomy PSA that failed to reach zero, and 1 
patient was noncompliant, leaving 66 patients for the final analysis (Appendix C). Baseline 
characteristics for the 66 participants are displayed in Table 1. Data on equol production were 
known for 35 men in the soy group out of the original 86 men. Out of these 35 patients, 10 
(29%) were equol producers. In the 66 men included in the analysis, 5 out of 25 (20%) were 
equol producers. 
 
Rate of recurrence 
Biochemical recurrence occurred in 6 patients (9%), including 3 in the soy group 
(9.3%) and 3 in the placebo group (8.8%). Characteristics of the six patients with 
biochemical recurrence are outlined in Table 2 (Appendix D). Rate of recurrence was not 
significantly different between soy and placebo groups (p = 0.63), nor did it differ 
between curative treatment types (RP: n = 5 [11%], RT: n = 1 [5%]) (p = 0.41). Finally, 
logistic regression analysis did not find an association between biochemical recurrence 
and soy/placebo or curative treatment types. 
Table 1. Baseline Characteristics 
Characteristic Soy Placebo 
Participants, no. 32 34 
Mean age, y 64 ± 7 63 ± 7 
Mean baseline PSA, ng/mL  8.76 ± 4.66 8.45 ± 4.74 
Gleason score, no.  6.8 ± 0.8 6.6 ± 0.7 
Body weight, lb 202 ± 37 208 ± 37 
Height, in.  70.2 ± 3 69.3 ± 3 
BMI, kg/m2  29 ± 5 30.5 ± 5 
Date represent Mean ± Standard Deviation. Means were compared using Mann-Whitney U test. No 
significant differences were found between soy and placebo groups. p < 0.05 was considered 
statistically significant. PSA = prostate-specific antigen; BMI = body mass index. 
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Time to recurrence 
Mean time to recurrence overall was 33 ± 22 months. Time to recurrence in the 
soy group was 27 ± 26 months, and in the placebo group was 40 ± 20 months (p = 0.53). 
Mean time to recurrence in men that underwent radical prostatectomy was 29 ± 22 
months, compared to 54 months in the one patient with recurrence that received radiation 
therapy (p = 0.36). Median time to recurrence overall was 34 months, with a median of 
20 months in the soy group, 48 months in the placebo group, and 20 months in the 
prostatectomy group. Individual times to recurrence are displayed in Appendix D. 
 Mean follow-up time, defined as time to last PSA (SD), was 50 ± 19 months. 
Biochemical recurrence was reported in 3 patients in each group. No significant 
differences were found between times to recurrence in the soy versus placebo groups 
(Log-rank p = 0.93) or curative treatment groups (Log-rank p = 0.29) (Appendix E).  
 Three patients in the soy group (9.3%) and 2 patients in the placebo group (5.9%) 
were deceased at the time chart reviews were completed. There was no significant 
difference in survival time between soy and placebo groups (Log-rank p = 0.62) or 
curative treatment groups (Log-rank p = 0.47) (Appendix E). 
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CHAPTER V: DISCUSSION 
Implications 
 Results of this study showed a 9% rate of biochemical recurrence overall, 9.3% in 
the soy group, and 8.8% in the placebo group. Previous data has found the natural history 
of prostate cancer leads to recurrence in 20-40% of men (14). Since the number of people 
who recurred was equal in the soy and placebo groups, it is unlikely this low rate of 
recurrence was due to soy isoflavone supplementation prior to curative treatment. 
Possible explanations for this low rate of recurrence include improved surgical 
techniques and short follow-up duration (range 4-7 years) that did not capture all those 
who may recur.  
 Mean time to recurrence in this study was 33 ± 22 months overall, 27 ± 26 
months in the soy group, 40 ± 20 months in the placebo group, and 29 ± 22 months for 
prostatectomy patients. When comparing only the five patients who had radical 
prostatectomy, the mean time to recurrence is slightly less than previous reports of 34 
months (29). The only patient with recurrence who underwent radiation therapy recurred 
at 54 months, which is greater than previous data that shows mean time to recurrence 
after radiation of 38 months (29).  
The overall median time to recurrence of 34 months, as well as a median of 20 
months in the prostatectomy group, in the present study are consistent with previous 
reports of 19-41 months for all treatments and 19-40 for prostatectomy alone 
(13,14,22,34). Time to recurrence in the placebo group could be skewed by the patient 
who underwent radiation therapy, as longer time to recurrence is usually seen after 
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radiation due to the definition of recurrence, which requires an increase of 2 ng/mL from 
PSA nadir.  
Limitations 
 Despite the strong design of the parent study, the present study had several 
limitations. First, duration of isoflavone intervention was short, ranging from 2-4 weeks. 
The soy isoflavone supplement used contained primarily daidzein instead of genistein, 
which makes it difficult to compare to other studies. Abstracting data from EMR 
introduces further limitations due to unavailable, missing, or incomplete information. 
Diet and physical activity were not monitored after curative treatment, nor is it known 
whether participants continued taking soy isoflavones after the study concluded. Based 
on previous data, the expected rate of recurrence was 20-40%, or 17-34 of the original 86 
participants. After exclusions, and with the relatively small recurrence rate in the current 
study, the study was not sufficiently powered to detect significance. Finally, mean 
follow-up time was 50 months, or approximately 4 years. Due to the greater time to 
recurrence in radiation versus prostatectomy patients in previous literature, the length of 
time to follow-up may not have been adequate to capture recurrence in this population.  
Future Research 
 Though this study failed to find significant results, it offers insight into how future 
studies can be improved. Learning from the limitations of this study, future studies 
should recruit larger sample sizes so the expected rate of recurrence includes enough 
participants to detect significance. The duration of isoflavone intervention should be 
varied to determine if longer interventions affect recurrence. Additionally, using a soy 
supplement with a greater percentage of genistein, the primary soy isoflavone used in 
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previous studies, may yield different results. Most importantly, this study can be analyzed 
with ancillary studies examining the effect of soy isoflavones on gene transcription to 
link clinical outcomes of the present to study to genetic markers. Comparing gene 
transcription in normal versus tumor tissue in soy and placebo groups will provide insight 
into individual responses to soy isoflavone supplementation and may help direct future 
research.  
Conclusion 
This is the first study to examine the effect of soy isoflavones prior to curative 
treatment on the natural history of prostate cancer. Short-term isoflavone 
supplementation prior to curative treatment was not found to prevent or delay 
biochemical recurrence in 66 men with localized prostate cancer, though time to 
recurrence in one patient from the placebo group who had radiation therapy was longer 
than times reported in previous literature, and no radiation patients in the soy group 
recurred at the time of data collection. Lack of significant results are likely due to the 
unusually low rate of recurrence in this study. Future research should link the clinical 
outcomes of this study to gene transcription to determine if soy isoflavones regulate cell 
signaling in prostate tissues. 
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Appendix A. REDCap Data Collection Form 
 
  www.project-redcap.org
Confidential
Soy and Prostate Cancer Study
Page 1 of 12
Demographics
Patient Demographics
Study ID __________________________________
Medical Record # __________________________________
First Name __________________________________
Last Name __________________________________
Date of Enrollment __________________________________
(Date of Initiation of Soy Treatment)
Date of Curative Treatment __________________________________
(YYYY-MM-DD)
Date of Birth __________________________________
(YYYY-MM-DD)
Race White
Black
Asian
Other
Ethnicity Hispanic or Latino
Non-hispanic or latino
Age __________________________________
Soy vs. Placebo Soy
Placebo
(Soy vs. placebo)
Lost to follow up Yes
No
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www.project-redcap.org
Confidential
Soy and Prostate Cancer Study
Page 2 of 12
Pre Op
Pre-Operative Data
PSA at Presentation __________________________________
Salvage Case After PreOp Radiation Yes
No
DNA
Pre-Op Hormones: Yes
No
unknown
(Examples: Lupron(leuprolide), Zoladex
(goserelin), Trelstar (triptorelin) Vantas
(histrelin) or Frimagon (degarelix))
Pre-Op 5-ARI use : Avodart/Proscar Yes
No
DNA
(Finasteride or Dutasteride)
Pre-Op Antibiotics Yes
No
(Antibiotic use within 6 weeks of treatment)
Pre-Op Antibiotics __________________________________
(Comments about type, time, duration, etc.)
T Clinical Stage 2010 TX
TO
T1A
T1B
T1C
T2A
T2B
T2C
T3A
T3B
T4
DNA
N Clinical Stage 2010 NX
N0
N1
DNA
M Clinical Stage 2010 MX
M0
M1
M1A
M1B
M1C
DNA
Gleasons Primary @ BX 1
2
3
4
5
DNA
	   33	  
 
  
www.project-redcap.org
Confidential
Page 3 of 12
Gleasons Secondary @ BX 1
2
3
4
5
DNA
Gleasons Sum @ BX __________________________________
D'Amico Risk Classification Very Low Risk
Low Risk
Intermediate Risk
High Risk
(Low - GS 6 or less, PSA 10 or less, T2a or less
Intermediate: Gl 7, PSA 10-20, T2a-T2b, High
Risk: Gl 8-10, PSA >20, T2c>)
 
Other Text __________________________________
Pre-Op Comments __________________________________
Height (inches) __________________________________
Screening weight (lbs) __________________________________
Screening BMI __________________________________
(BMI at initial evaluation)
Pre-Treatment Weight (lbs) __________________________________
Pre-Treatment BMI __________________________________
(BMI at time of curative treatment)
Comorbidities at time of surgery Hypertension
Dyslipidemia
Diabetes I/II
Cardiovascular Disease
Peripheral Vascular Disease
Cerebrovascular Disease
Congestive Heart Failure
Pulmonary disease (asthma, COPD, reactive airway
disease, obstructive sleep apnea)
Other
None
Other Comorbidities __________________________________
(If not listed above)
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www.project-redcap.org
Confidential
Soy and Prostate Cancer Study
Page 4 of 12
Charlson Comorbidity Index
Comorbidity (Choose all that are present)brbrAssigned Myocardial infarct (+1)
weights for each condition the patient has ( ) Congestive heart failure (+1)
Peripheral vascular disease (+1)
Cerebrovascular disease (except hemiplegia) (+1)
Dementia (+1)
Chronic pulmonary disease (+1)
Connective tissue disease (+1)
Ulcer disease (+1)
Mild liver disease (+1)
Diabetes (without complications) (+1)
Diabetes with end organ damage (+2)
Hemiplegia (+2)
Moderate or severe renal disease (+2)
Solid tumor (non metastatic) (+2)
Leukemia (+2)
Lymphoma, Multiple myeloma (+2)
Moderate or severe liver disease (+3)
Metastatic solid tumor (+6)
AIDS (+6)
Age 50 - 59 (+1)
60 - 69 (+2)
70 - 79 (+3)
80 - 89 (+4)
90 - 99 (+5)
Comments: __________________________________
Total points: __________________________________
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www.project-redcap.org
Confidential
Soy and Prostate Cancer Study
Page 5 of 12
Treatment Modality
Treatment Radical Prostatectomy
External Beam Radiation
Interstitial Brachytherapy
Active Survillence/Watchful Waiting
Other
(If Radical Prostatectomy Selected Proceed to
Surgical Data Collection Form)
Other Treatment __________________________________
Surgical Approach Robotic/Laparoscopic
Retropubic
Perineal
Lap converted to open
unknown
Concurrent Androgen Deprivation Therapy? Yes
No
Length of hormonal therapy (months) 3-6
7-12
13-24
>24
Date of ADT __________________________________
(Date of first dose ADT)
Last known dose of ADT __________________________________
(Last dose ADT administered)
Date of Radiation Therapy Start __________________________________
Date Radiation Therapy Complete __________________________________
PSA nadir __________________________________
(Lowest PSA after treatment)
Date of PSA Nadir __________________________________
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www.project-redcap.org
Confidential
Soy and Prostate Cancer Study
Page 6 of 12
Post Op
Minor Complications
Minor Complications Yes
No
DNA
Check all that apply DVT
Urine Leak
Pneumonia
Ileus
Other
Other Minor Complication(s): __________________________________
Major Complications
Major Complications Yes
No
DNA
Check all that apply MI
PE
CVA
Return to OR
Death
Other
Other Major Complication(s): __________________________________
Post-Op Dietary Supplements __________________________________
(List any dietary supplements taken post-op)
Post-Op Comments __________________________________
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www.project-redcap.org
Confidential
Soy and Prostate Cancer Study
Page 7 of 12
Path
Pathology - Please note only those whom had surgery will have information for below.
Gleasons Primary PostOp 1
2
3
4
5
DNA
Gleasons Secondary PostOp 1
2
3
4
5
DNA
Gleason Tertiary PostOp 1
2
3
4
5
DNA
Gleasons Sum PostOp __________________________________
 
Margin Status negative
positive
DNA
 
Pathological Tumor Stage 2010 TX
T0
T2A
T2B
T2C
T3A
T3B
T4
DNA
AJCC Stage 2010 I
IIA
IIB
III
IV
DNA
Seminal vesicle invasion Yes
No
DNA
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www.project-redcap.org
Confidential
Page 8 of 12
Nodal Involvement
Pathological Nodal Stage 2010 Nx
N0
N1
N2
N3
 If positive lymph nodes, assess whether patient started on hormonal therapy.
If gleason score >7, positive margins, OR T3 disease or greater, assess whether patient given
adjuvant radiation.
Distant Metastasis PCS
pM0
pM1
pM1A
pM1B
pM1C
Bladder Neck Invasion Microscopic
Gross
None
DNA
Extracapsular extension Yes
No
DNA
Path Comments __________________________________
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www.project-redcap.org
Confidential
Soy and Prostate Cancer Study
Page 9 of 12
Follow Up
Look at PSA labs and evaluate profile. PSA after surgery should be 
Last Follow up __________________________________
(Date of last encounter)
PSA at last follow up __________________________________
Date of Last PSA __________________________________
(if other than date of last follow up)
Biochemical Recurrence Yes
No
(For radiation, biochemical recurrence is nadir
+2.  For surgery PSA >0.2)
Date of documented biochemical recurrence __________________________________
Time to Recurrence (months) __________________________________
Time to Last PSA (months) __________________________________
(Months from curative treatment to last PSA)
Adjuvant Treatment Administered? Yes
No
(This would be any treatment given after curative
treatment PRIOR to PSA recurrence)
Adjuvant Treatment Type Radiation
Androgen Deprivation Therapy
Other
Date of Start of Adjuvant Treatment __________________________________
Salvage Treatment Yes
No
(Any treatment (hormones, surgery, radiation)
given AFTER PSA recurrence)
Salvage Treatment(s) Radiation
Surgery
Hormonal ablation
other
Other Comorbidities __________________________________
(If not listed above)
Alive? Yes
No
Did patient die from prostate cancer? Yes
No
Unknown
Cause of death __________________________________
(if not from prostate cancer)
Date of Death __________________________________
Age at Death __________________________________
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www.project-redcap.org
Confidential
Page 10 of 12
Time to Death (months) __________________________________
(Time from curative treatment to death)
Disease status at death No evidence of biochemical recurrence
No evidence of metastatic disease
Biochemical recurrence but no measurable disease
Biochemical recurrence and measurable disease
other
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www.project-redcap.org
Confidential
Soy and Prostate Cancer Study
Page 12 of 12
Urinary Isoflavone Concentration
Urinary Creatinine Concentration __________________________________
ODMA __________________________________
ODMA Creatinine Adjusted __________________________________
Equol Producer Yes
No
Equol Concentration __________________________________
Equol Creatinine Adjusted __________________________________
Log 10 Equol __________________________________
DHD __________________________________
DHD Creatinine Adjusted __________________________________
Daidzein __________________________________
Daidzein Creatinine Adjusted __________________________________
Genistein __________________________________
Genistein Creatinine Adjusted __________________________________
Glycitein __________________________________
Glycitein Creatinine Adjusted __________________________________
Compliant to intervention Yes
No
Compliance Comments __________________________________
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Appendix B. Boxplots 
 
Time to Recurrence in Soy vs. Placebo Groups 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Time to Recurrence in Prostatectomy vs. Radiation 
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Appendix	  C:	  CONSORT	  Diagram	  
	  
	  
	  
	  
Lost	  =	  Lost	  to	  follow-­‐up,	  PD	  =	  persistent	  disease	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analysis	  
Exclusion	  
Treatment	  
AS	  excluded	  
Soy:	  n	  =	  2	  
Placebo:	  n	  =	  1	  	  
Allocation	  
Enrollment	   Randomized	  n	  =	  86	  
Soy	  
n	  =	  42	  
Prostatectomy	  
n	  =	  30	  
Lost	  n	  =	  3	  
PD*	  n	  =	  4	  
Analyzed	  
n	  =	  23	  
Radiation	  
n	  =	  10	  
Lost	  n	  =	  1	  
Analyzed	  
n	  =	  9	  
Placebo	  	  
n	  =	  44	  
Prostatectomy	  
n	  =	  29 	  	  
Lost	  n	  =	  1	  
PD	  n	  =	  4	  
Noncompliant	  n	  =	  1	  
Analyzed	  
n	  =	  23	  
Radiation	  
n	  =	  14	  
Lost	  n	  =	  3	  
Analyzed	  
n	  =	  11	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Appendix D. Baseline Characteristics of Patients with Biochemical Recurrence	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Appendix	  E.	  Kaplan-­‐Meier	  Plots	  
	  
	   	  
	   Time	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   Survival	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